Posted by Michael Wonder on 04 Jan 2018
Xiidra (lifitegrast ophthalmic solution 5%) approved by Health Canada to treat the signs and symptoms of dry eye disease
3 January 2018 - Canada approval represents Shire’s first international market authorisation for Xiidra outside of the United States.
Shire announced today that Xiidra (lifitegrast ophthalmic solution 5%), a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adults, has been approved in Canada, marking the first international approval for the treatment outside of the U.S.
Xiidra is the first new prescription medication for dry eye disease to be approved in Canada in seven years, providing patients with an effective treatment option for this common eye disease.
